Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study

Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study

IntroductionGiven that obstructive sleep apnea (OSA) is commonly associated with metabolic disorders, in this prospective study, we sought to determine the prevalence and risk factors for hepatosteatosis, non-alcoholic steatohepatitis (NASH), and advanced liver fibrosis in patients with clinical and...

Full description

Bibliographic Details
Main Authors:	Pedro Landete, Carlos Ernesto Fernández-García, Beatriz Aldave-Orzaiz, Marta Hernández-Olivo, Carmen M. Acosta-Gutiérrez, Enrique Zamora-García, Julio Ancochea, Águeda González-Rodríguez, Carmelo García-Monzón
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-02-01
Series:	Frontiers in Medicine
Subjects:	non-alcoholic fatty liver disease steatosis non-alcoholic steatohepatitis obstructive sleep apnea syndrome nocturnal intermittent hypoxia
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.808417/full

Similar Items

Sleep apnea-COPD overlap syndrome is associated with larger left carotid atherosclerotic plaques
by: Pedro Landete, et al.
Published: (2023-03-01)

β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats
by: Janet Sánchez-Quevedo, et al.
Published: (2022-09-01)

Obesity-related non-alcoholic steatohepatitis and TGF-β1 serum levels in relation to morbid obesity
by: Ricardo N Sepúlveda-Flores, MD, et al.
Published: (2002-01-01)

NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Published: (2012-04-01)

Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy
by: Zhi-Ming Ding, et al.
Published: (2018-05-01)

Corrigendum: Progression and Regression of Hepatic Lesions in a Mouse Model of NASH Induced by Dietary Intervention and Its Implications in Pharmacotherapy
by: Zhi-Ming Ding, et al.
Published: (2020-02-01)

The effect of chronic intermittent hypoxia in the evolution of NASH
by: Amal Abd El-Azeem I., et al.
Published: (2012-07-01)

Metabolic preconditions for the formation and progression of steatohepatitis of alcoholic, mixed, non-alcoholic aetiology and their comorbidity with obesity and anaemic conditions
by: T. Antofiichuk, et al.
Published: (2023-05-01)

Preventing NASH with Empagliflozin and Linagliptin: A Diabetic Drug Combination
by: Asma Abdul Razzak, et al.
Published: (2023-10-01)

THE COURSE OF CHRONIC KIDNEY DISEASE (CHRONIC PYELONEPHRITIS) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY
by: Aliona A. Antoniv, et al.
Published: (2021-09-01)

Evaluation of thrombocytopenia in patients with non-alcoholic fatty liver disease without cirrhosis
by: Carine L. Panke, et al.
Published: (2020-01-01)

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
by: Cristina Piras, et al.
Published: (2021-10-01)

Improvement of Diagnostic Algorithm in Patients With Alcoholic Fatty Liver Disease by Using Non-invasive Methods of Verification of Liver Steatosis and Fibrosis
by: Svintsitskyy A., et al.
Published: (2016-07-01)

USING NON-INVASIVE BIOMARKERS AND PLACE OF CYTOKERATIN 18 IN DIAGNOSIS PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
by: N. V. Dynnyk
Published: (2016-04-01)

Ultrasound radiomics-based logistic regression model for fibrotic NASH
by: Fei Xia, et al.
Published: (2025-02-01)

Markedly lower follow-up rate after liver biopsy in patients with non-alcoholic fatty liver diseases than those with viral hepatitis in Japan
by: Hisanaga Yasuhiro, et al.
Published: (2011-09-01)

High prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity
by: Sven Pischke, et al.
Published: (2023-03-01)

Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
by: Ryan D. Welch, et al.
Published: (2022-03-01)

Deciphering the Effective Constituents and Mechanisms of Portulaca oleracea L. for Treating NASH via Integrating Bioinformatics Analysis and Experimental Pharmacology
by: Xiaoli He, et al.
Published: (2022-01-01)

Binary Bacillus subtilis protects the intestinal mucosa barrier and alleviates nonalcoholic steatohepatitis
by: Donglin Liu, et al.
Published: (2024-06-01)

Prevalence of non-alcoholic fat disease liver in Russian Federation: meta-analysis
by: Igor V. Maev, et al.
Published: (2023-08-01)

Hepatic transcriptome profiling reveals early signatures associated with disease transition from non-alcoholic steatosis to steatohepatitis
by: Nancy Magee, et al.
Published: (2022-12-01)

S-adenosylmethionine metabolism and liver disease
by: José M. Mato, et al.
Published: (2013-03-01)

New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation
by: Antônio R. Andrade, et al.
Published: (2017-11-01)

Current and Potential Therapies Targeting Inflammation in NASH
by: Somaya Albhaisi, et al.
Published: (2021-12-01)

Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial
by: Elizabeth A. Brown, et al.
Published: (2023-04-01)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
by: Stephen Caldwell
Published: (2017-06-01)

Higher Risk of Tumor Recurrence in NASH-Related Hepatocellular Carcinoma Following Curative Resection
by: Shih-Chieh Chien, et al.
Published: (2022-10-01)

The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH
by: Ryan J. Dashek, et al.
Published: (2021-10-01)

Periostin Circulating Levels and Genetic Variants in Patients with Non-Alcoholic Fatty Liver Disease
by: Carlo Smirne, et al.
Published: (2020-11-01)

Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease
by: Yamei Duan, et al.
Published: (2022-05-01)

Editor’s Pick: Non-Alcoholic Fatty Liver Disease – Changing the Prevalence of Liver Cancer?
by: Benedetta Campana, et al.
Published: (2015-01-01)

Structure of anaemic conditions comorbid to alcoholic and non-alcoholic steatohepatitis
by: Oksana Khukhlina, et al.
Published: (2021-05-01)

The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study
by: Osama Hamid, et al.
Published: (2022-09-01)

Editorial: New Insights Into Understanding and Managing NAFLD
by: Óscar Escribano, et al.
Published: (2021-11-01)

Association between gut microbiota and NAFLD/NASH: a bidirectional two-sample Mendelian randomization study
by: Qilong Zhai, et al.
Published: (2023-12-01)

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients
by: Singh Deepak, et al.
Published: (2010-07-01)

Salidroside may target PPARα to exert preventive and therapeutic activities on NASH
by: Xueru Chu, et al.
Published: (2024-10-01)

The diagnostic conundrum in non-alcoholic fatty liver disease
by: Valerio Rosato, et al.
Published: (2020-10-01)

SENSITIVITY AND SPECIFICITY OF VECTORCARDIOGRAPHY IN DIAGNOSTICS OF ACUTE MYOCARDIAL INFARCTION COMORBID WITH LIVER STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS
by: I. E. Belaya, et al.
Published: (2015-12-01)